Expected value of artificial intelligence in gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement

  • Helmut Messmann
    III Medizinische Klinik, Universitatsklinikum Augsburg, Augsburg, Germany
  • Raf Bisschops
    Department of Gastroenterology and Hepatology, Catholic University of Leuven (KUL), TARGID, University Hospital Leuven, Leuven, Belgium
  • Giulio Antonelli
    Gastroenterology and Digestive Endoscopy Unit, Ospedale dei Castelli Hospital, Ariccia, Rome, Italy
  • Diogo Libânio
    Department of Gastroenterology, Porto Comprehensive Cancer Center, and RISE@CI-IPOP (Health Research Network), Porto, Portugal
  • Pieter Sinonquel
    Department of Gastroenterology and Hepatology, Catholic University of Leuven (KUL), TARGID, University Hospital Leuven, Leuven, Belgium
  • Mohamed Abdelrahim
    Endoscopy Department, Portsmouth Hospitals University NHS Trust, Portsmouth, UK
  • Omer F. Ahmad
    Wellcome/EPSRC Centre for Interventional and Surgical Sciences, University College London Hospital, London, UK
  • Miguel Areia
    Gastroenterology Department, Portuguese Oncology Institute of Coimbra, Coimbra, Portugal
  • Jacques J. G. H. M. Bergman
    Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands
  • Pradeep Bhandari
    Endoscopy Department, Portsmouth Hospitals University NHS Trust, Portsmouth, UK
  • Ivo Boskoski
    Digestive Endoscopy Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
  • Evelien Dekker
    Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands
  • Dirk Domagk
    Department of Medicine I, Josephs-Hospital Warendorf, Academic Teaching Hospital, University of Muenster, Warendorf, Germany
  • Alanna Ebigbo
    III Medizinische Klinik, Universitatsklinikum Augsburg, Augsburg, Germany
  • Tom Eelbode
    Department of Electrical Engineering (ESAT/PSI), Medical Imaging Research Center, KU Leuven, Leuven, Belgium
  • Rami Eliakim
    Department of Gastroenterology, Sheba Medical Center Tel Hashomer & Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel
  • Michael Häfner
    2nd Medical Department, Barmherzige Schwestern Krankenhaus, Vienna, Austria
  • Rehan J. Haidry
    Wellcome/EPSRC Centre for Interventional and Surgical Sciences, University College London Hospital, London, UK
  • Rodrigo Jover
    Servicio de Gastroenterología, Hospital General Universitario Dr. Balmis, Instituto de Investigación Biomédica de Alicante ISABIAL, Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain
  • Michal F. Kaminski
    Clinical Effectiveness Research Group, University of Oslo, Oslo, Norway
  • Roman Kuvaev
    Endoscopy Department, Yaroslavl Regional Cancer Hospital, Yaroslavl, Russian Federation
  • Yuichi Mori
    Clinical Effectiveness Research Group, University of Oslo, Oslo, Norway
  • Maxime Palazzo
    European Hospital, Marseille, France
  • Alessandro Repici
    Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy
  • Emanuele Rondonotti
    Gastroenterology Unit, Valduce Hospital, Como, Italy
  • Matthew D. Rutter
    North Tees and Hartlepool NHS Foundation Trust, Stockton-on-Tees, UK
  • Yutaka Saito
    Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan
  • Prateek Sharma
    Gastroenterology and Hepatology Division, University of Kansas School of Medicine, Kansas, USA
  • Cristiano Spada
    Digestive Endoscopy Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
  • Marco Spadaccini
    Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy
  • Andrew Veitch
    Department of Gastroenterology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK
  • Ian M. Gralnek
    Ellen and Pinchas Mamber Institute of Gastroenterology and Hepatology, Emek Medical Center, Afula, Israel
  • Cesare Hassan
    Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy
  • Mario Dinis-Ribeiro
    Department of Gastroenterology, Porto Comprehensive Cancer Center, and RISE@CI-IPOP (Health Research Network), Porto, Portugal

説明

<jats:title>Abstract</jats:title><jats:p>This ESGE Position Statement defines the expected value of artificial intelligence (AI) for the diagnosis and management of gastrointestinal neoplasia within the framework of the performance measures already defined by ESGE. This is based on the clinical relevance of the expected task and the preliminary evidence regarding artificial intelligence in artificial or clinical settings.</jats:p><jats:p> Main recommendations: (1) For acceptance of AI in assessment of completeness of upper GI endoscopy, the adequate level of mucosal inspection with AI should be comparable to that assessed by experienced endoscopists. (2) For acceptance of AI in assessment of completeness of upper GI endoscopy, automated recognition and photodocumentation of relevant anatomical landmarks should be obtained in ≥90% of the procedures. (3) For acceptance of AI in the detection of Barrett’s high grade intraepithelial neoplasia or cancer, the AI-assisted detection rate for suspicious lesions for targeted biopsies should be comparable to that of experienced endoscopists with or without advanced imaging techniques. (4) For acceptance of AI in the management of Barrett’s neoplasia, AI-assisted selection of lesions amenable to endoscopic resection should be comparable to that of experienced endoscopists. (5) For acceptance of AI in the diagnosis of gastric precancerous conditions, AI-assisted diagnosis of atrophy and intestinal metaplasia should be comparable to that provided by the established biopsy protocol, including the estimation of extent, and consequent allocation to the correct endoscopic surveillance interval. (6) For acceptance of artificial intelligence for automated lesion detection in small-bowel capsule endoscopy (SBCE), the performance of AI-assisted reading should be comparable to that of experienced endoscopists for lesion detection, without increasing but possibly reducing the reading time of the operator. (7) For acceptance of AI in the detection of colorectal polyps, the AI-assisted adenoma detection rate should be comparable to that of experienced endoscopists. (8) For acceptance of AI optical diagnosis (computer-aided diagnosis [CADx]) of diminutive polyps (≤5 mm), AI-assisted characterization should match performance standards for implementing resect-and-discard and diagnose-and-leave strategies. (9) For acceptance of AI in the management of polyps ≥ 6 mm, AI-assisted characterization should be comparable to that of experienced endoscopists in selecting lesions amenable to endoscopic resection.</jats:p>

収録刊行物

  • Endoscopy

    Endoscopy 54 (12), 1211-1231, 2022-10-21

    Georg Thieme Verlag KG

参考文献 (117)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ